Press Releases Subscribe to our News
28 August 2023
Regulatory
Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million
Release
22 August 2023
Regulatory
The last day of trading in warrants series TO2 in Biosergen AB is today, August 22, 2023
Release
16 August 2023
Regulatory
Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management
Release
14 August 2023
Regulatory
Biosergen publishes interim report for first quarter 2023
ReleaseQ2-2023 Financial Report
11 August 2023
Regulatory
The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023
Release
07 August 2023
Regulatory
Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)
Release
31 May 2023
Regulatory
Biosergen publishes interim report for first quarter 2023
ReleaseQ1-2023 Financial Report
10 May 2023
28 April 2023
31 March 2023
Regulatory
Biosergen publishes interim report for fourth quarter 2022
ReleaseQ4-2022 Financial Report
29 March 2023
30 November 2022
Regulatory
Biosergen publishes interim report for third quarter 2022
ReleaseQ3-2022 Financial Report
04 October 2022
08 September 2022
Regulatory
Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study.
Release
02 September 2022
Regulatory
Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million
Release
31 August 2022
Regulatory
Biosergen publishes interim report for second quarter 2022
ReleaseQ2-2022 Financial Report
26 August 2022
30 June 2022
28 June 2022
Regulatory
Announcement from the annual general meeting held on June 28, 2022 in Biosergen AB
Release
07 June 2022
31 May 2022
Regulatory
Biosergen publishes interim report for first quarter 2022
Release2022-Q1 Financial Report
13 May 2022
07 April 2022
31 March 2022
Regulatory
Biosergen publishes interim report for fourth quarter 2021
Biosergen Q4 financial report press releaseQ4-2021 Financial Report
30 November 2021
Regulatory
Biosergen publishes interim report for the third quarter 2021
Q3-2021 Financial ReportBiosergen Q3 financial report press release
31 August 2021
Regulatory
Biosergen publishes interim report for the second quarter 2021
Q2-2021 Financial ReportBiosergen Q2 report press release
27 June 2021
Regulatory
Biosergen’s groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the United States
Release
08 June 2021
